Nebenwirkungen · Privigen
Privigen 100 mg/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-118946 · Präparat HOS-094881
Seven clinical studies were performed with Privigen, which included patients with PID, ITP and CIDP. In the pivotal PID study, 80 patients were enrolled and treated with Privigen. Of these, 72 completed the 12 months of treatment. In the PID extension study, 55 patients were enrolled and treated with Privigen. Another clinical study included 11 PID patients in Japan. Two ITP studies were performed with 57 patients each. Two CIDP studies were performed with 28 and 207 patients, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-24T02:00:00Z · SHA-256 208a630b72cbe4bf06dce638906eae5709b3d2c4ac99de003201ffa973213cd0 · Passage 76f601f7e0da04bd894e2012f445a0478f16d5a6c7a697ca9dd40907b1779fe6 · Zeichen 1238–1733 im Abschnitt